Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
April 29 (Reuters) - Zyversa Therapeutics Inc ZVSA.O:
ZYVERSA THERAPEUTICS ANNOUNCES PUBLISHED DATA SHOWING INFLAMMASOME ASC INHIBITOR IC 100 DECREASES MICROGLIAL INFLAMMASOME ACTIVATION AND ALPHA-SYNUCLEIN THAT CONTRIBUTE TO NEURODEGENERATION IN PARKINSON’S DISEASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

Why SanDisk Stock Could Soar to $4,000?

Tradingkey







